(SBFM) Sunshine Biopharma, Inc. Business Model Canvas Research

Regulatory and clinical advisors help Sunshine Biopharma, Inc. handle IND filings, safety reviews, and trial design so its oncology and antiviral programs stay aligned with FDA and other market rules. With drug development often taking 10+ years and costing well over $1 billion, these partners can cut delay risk and improve the odds of advancing the pipeline.

• Support FDA filings and safety work
• Refine trial design and endpoints
• Reduce launch and compliance risk

Sunshine Biopharma, Inc. depends on distribution and retail partners to place Essential 9 and Essential Calcium-Vitamin D in online sellers and health retailers, reaching buyers without building a large direct-sales team. That matters in a market where U.S. e-commerce still took 16.2% of total retail sales in Q1 2025.

• وسع reach through online channels
• Boosts shelf access at health retailers
• Lowers direct sales cost burden

Sunshine Biopharma, Inc. uses preclinical and translational studies to prove efficacy, safety, and mechanism in each target indication before clinic entry. This step bridges discovery to clinical readiness and matters because only about 10% of drug candidates that enter development reach approval, so strong preclinical data can raise pipeline value.

• Tests efficacy, safety, and mechanism
• Links discovery to clinic-ready assets
• Supports pipeline value creation

Quality and regulatory execution is central for Sunshine Biopharma, Inc. because drug and supplement lines both depend on strict documentation, accurate labeling, and GMP-style quality systems. These controls support faster commercialization and lower recall, warning-letter, and launch-delay risk.

• Quality systems
• Labeling control
• Regulatory planning

Sunshine Biopharma, Inc.'s key resource is scientific know-how: chemistry, screening, and product design turn research into proprietary formulations that can support differentiation and future licensing or product sales. Its IP matters because patents and formulation rights can protect margins and help convert R&D into monetizable assets.

• Research capability drives formulation design.
• IP helps protect differentiation.
• Monetization can follow licensing or sales.

Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Quebec, and this site anchors management, coordination, and corporate operations. It also supports both scientific work and commercial activity, making it a core Key Resource in the Business Model Canvas.

• Base for management and coordination
• Supports scientific and commercial activity
• Located in Pointe-Claire, Canada

Sunshine Biopharma, Inc.'s science-based nutrition products turn formulation work into a non-pharma revenue stream. Essentials like Essential 9 and Essential Calcium-Vitamin D target health-conscious buyers in a global dietary supplements market that was about $177 billion in 2024 and is projected to reach $327 billion by 2030.

• Backed by product formulation work
• Targets wellness-focused buyers
• Builds non-pharma sales

Sunshine Biopharma, Inc.'s dual portfolio model pairs long-cycle drug development with current consumer products, so pipeline risk is not tied to one revenue source. That matters in a small-cap biotech because near-term product sales can help fund R&D while the drug pipeline keeps the long-term upside open.

• Balances R&D risk with sales
• Supports nearer-term cash flow
• Broadens the market story

Sunshine Biopharma, Inc. must keep healthcare and research partners aligned with clear, auditable updates on study progress, product claims, and compliance status. In a regulated market where ClinicalTrials.gov tracks more than 500,000 studies, precise technical communication helps protect trust and speed partner decisions.

• Share study milestones fast and clearly.
• Back claims with traceable data.
• Keep compliance updates easy to verify.

Supplement buyers tend to reorder when they trust product quality, so Sunshine Biopharma, Inc. must keep branding and formulations consistent. In a repeat-purchase category like health products, reliability and visible product performance are what turn one-time buyers into loyal customers.

• Keep branding stable across batches
• Prove formulation quality each time
• Build trust through repeat performance

Sunshine Biopharma, Inc. relies on academic and clinical networks to move drug programs from research labs into patient care settings, where data are generated and findings are validated. In 2025, ClinicalTrials.gov listed over 520,000 studies, showing how vital these channels are for trial readiness and pipeline progress.

• Feeds early data and external validation
• Supports future trial recruitment
• Reduces time to pipeline milestones

Sunshine Biopharma, Inc. can use partner licensing routes to move pre-commercial drug candidates to market faster, while avoiding the full cost of in-house sales and distribution. This model fits assets that still need funding, scale, or regulatory help, and it can swap early development risk for upfront, milestone, and royalty income.

• Best for pre-commercial assets
• Speeds development and approval
• Reduces launch capital needs

Clinical and academic researchers are a fit for Sunshine Biopharma, Inc.'s oncology and antiviral programs, where university labs can help with validation, testing, and publication. The University of Georgia collaboration shows this segment in action, giving the Company a research channel across 2 core program areas.

• Validates preclinical results
• Supports publishable data
• Covers oncology and antivirals
• University of Georgia is a key example

Future therapy patients are the long-term end users if Sunshine Biopharma, Inc.'s pipeline works, especially people with cancer or coronavirus-related disease. Adva-27a and SBFM-PL4 are the core assets for this segment, which matters in a global cancer market with about 20 million new cases a year and a continuing need for antiviral options.

• End users: cancer and COVID-related patients
• Core assets: Adva-27a, SBFM-PL4
• Value driver: successful clinical results

Sunshine Biopharma, Inc. faces steady regulatory and compliance overhead because pharma and supplement products must meet FDA cGMP, labeling, filing, and legal-review rules. These costs are recurring, not optional, and they protect the business from recalls, warning letters, and launch delays.

• Filings and documentation
• Labeling and claims review
• Legal and quality control
• Risk reduction for launches

Sunshine Biopharma, Inc. uses selling and administrative overhead to run its Pointe-Claire headquarters, pay staff, and support sales and compliance, so this cost base also feeds R&D execution. In the latest FY2025 reports, overhead stayed a core cash use alongside product rollout and research spend, which makes control of G&A essential to margin recovery.

• Headquarters and staff costs
• Commercial and admin support
• Backs both R&D and sales

Collaboration and milestone income gives Sunshine Biopharma, Inc. non-dilutive cash, so research partners can help fund R&D without issuing more shares. The University of Georgia collaboration shows how external support can back development work and, if milestones are met, help offset lab and regulatory costs.

• Non-dilutive funding
• Milestone-linked cash
• Offsets R&D spend

Adva-27a and SBFM-PL4 are Sunshine Biopharma, Inc.'s high-upside assets: if they reach the clinic and win partners, they can generate upfront license fees, milestone payments, and long-tail royalties. That model matters because biotech deals often shift value from current cash burn to future product economics, with royalties commonly running in the low-single-digit to mid-teens percent range.

• Upfront fees can fund development.
• Milestones pay on progress.
• Royalties scale with sales.
• Partnerships reduce funding risk.